Stockscreener 앱 받기
28.40
4.41%
1.20
시간 외 거래:
28.40
전일 마감가:
$27.20
열려 있는:
$27
하루 거래량:
2.97M
Relative Volume:
1.51
시가총액:
$4.73B
수익:
$1.48B
순이익/손실:
$241.66M
주가수익비율:
19.83
EPS:
1.4325
순현금흐름:
$480.33M
1주 성능:
+2.75%
1개월 성능:
-11.25%
6개월 성능:
+2.20%
1년 성능:
-17.30%
1일 변동 폭
$27.00
$28.49
1주일 범위
$27.00
$28.51
52주 변동 폭
$25.16
$36.32
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.40 | 4.53B | 1.48B | 241.66M | 480.33M | 1.4325 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-11-11 | 개시 | Truist | Buy |
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Big Picture: Can Alkermes plc stock outperform in a bear marketMarket Movers & Expert Approved Trade Ideas - baoquankhu1.vn
Alkermes outlines $1.73B–$1.84B 2026 revenue target as Avadel acquisition expands commercial reach - MSN
Alkermes announces inaugural Alkermes Pathways APN Research Awards™ program - MSN
Alkermes shares rise after revenue beat and upbeat outlook offsets earnings miss - MSN
Alkermes plc (ALKS) Latest Stock News & Headlines - Yahoo Finance
Alkermes CEO Pops Calls 2026 a “Really Exciting Year” as Orexin Agonists Near Narcolepsy Launch - MarketBeat
Layoff Watch: Does Alkermes plc offer margin of safety2026 Volatility Report & Consistent Growth Equity Picks - baoquankhu1.vn
Holocene Advisors LP Cuts Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes appoints new CFO - MSN
How Alkermes Plc (ALKS) Affects Rotational Strategy Timing - Stock Traders Daily
Farallon Capital Management LLC Has $624,000 Stock Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes plc Stock (ISIN: IE00B56GVS15) Under Pressure After Avadel Acquisition—Wells Fargo Raises - AD HOC NEWS
Alkermes plc $ALKS is Commodore Capital LP's 7th Largest Position - MarketBeat
Baker BROS. Advisors LP Boosts Holdings in Alkermes plc $ALKS - MarketBeat
Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation - MSN
Avoro Capital Advisors LLC Trims Position in Alkermes plc $ALKS - MarketBeat
Is Alkermes (ALKS) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance
Market Outlook: Will Alkermes plc outperform its industry peers2026 Summary & Long-Term Growth Plans - baoquankhu1.vn
Victory Capital Management Inc. Has $10.33 Million Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program - The Joplin Globe
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com
Alkermes to Present at the Stifel 2026 Virtual CNS Forum - BioSpace
ALKS Technical Analysis & Stock Price Forecast - Intellectia AI
Citigroup Inc. Sells 121,945 Shares of Alkermes plc $ALKS - MarketBeat
Is Alkermes’ Slower Q4 and CEO Transition Reshaping Its Orexin Strategy and Investment Case (ALKS)? - simplywall.st
Rhenman & Partners Asset Management AB Buys 55,000 Shares of Alkermes plc $ALKS - MarketBeat
Neuberger Berman Group LLC Has $4.58 Million Holdings in Alkermes plc $ALKS - MarketBeat
Why analysts are rating Alkermes (ALKS) a buy - MSN
Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch - TipRanks
Alkermes announces CEO succession plan - MSN
Alkermes plc (NASDAQ:ALKS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Avadel Pharmaceuticals Shares Climb on $2.1 Billion Acquisition by Alkermes - MSN
(ALKS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - Stocktwits
Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock - MarketBeat
Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Alkermes (ALKS) EVP Gaffin sells 4,068 shares and receives large option and RSU grants - Stock Titan
TD Asset Management Inc Sells 91,772 Shares of Alkermes plc $ALKS - MarketBeat
2,034-share Rule 144 sale by Alkermes insider (NASDAQ: ALKS) - Stock Titan
ALKS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celebrating LGBTQIA+ Mental Health Trailblazers - CSRwire
Alkermes Reports 2025 Financials, Advances Narcolepsy Pipeline, Announces CEO Succession - Sleep Review
Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen - Yahoo Finance
Alkermes (NASDAQ: ALKS) insider sells common stock via Form 144 - Stock Titan
Alkermes (ALKS) Rule 144: Insider sale notice for 6,000 shares, $180K - Stock Titan
5,000-share exercise and multiple sales reported by Alkermes (ALKS) - Stock Titan
Alkermes at TD Cowen: Strategic Shift to Sleep Medicine - Investing.com
Alkermes Plc (ALKS) Stock Analysis: Exploring A 45% Potential Upside In Biopharma - DirectorsTalk Interviews
American Century Companies Inc. Purchases 740,248 Shares of Alkermes plc $ALKS - MarketBeat
Alkermes Releases Third Annual Corporate Responsibility Report - CSRwire
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):